CurrentPremera BluecrossPolicy N/A

Pharmacologic Treatment of Postpartum Depression

Defines medical necessity, administration, and coverage limitations for brexanolone (Zulresso) IV and zuranolone (Zurzuvae) oral for treating postpartum depression for Premera members.

Policy Summary

PayerPremera Bluecross

PolicyPharmacologic Treatment of Postpartum Depression

Policy CodePolicy N/A

Change TypeAge eligibility expandedZurzuvae addedAuthorization clarification

Effective DateMar: 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization and document DSM-5 criteria plus severity (narrative or standardized scale) when requesting Zulresso or Zurzuvae.

SourceLink

POLICY UPDATE CHANGES

Updated age eligibility for Zulresso from 18 years or older to 15 years or older and added information defining moderate to severe depression.

Added zuranolone (Zurzuvae) for the treatment of postpartum depression in adults.

Clarified that non-formulary exception review authorizations for all drugs listed in this policy may be approved up to 12 months.

60 hZulresso infusion duration

14 daysZurzuvae course length

11.5%PPD prevalence (US)

26.5%Somnolence rate (zuranolone)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

12 moMax authorization (non-formulary)

Coverage Criteria for Brexanolone (Zulresso) and Zuranolone (Zurzuvae)

Initial Therapy (Zulresso and Zurzuvae)

Covered when ALL of the following are met:

Zulresso (brexanolone) initial therapy: Individual is aged 15 years or older; medical record documents DSM-5 diagnostic criteria for Major Depressive Disorder with peripartum onset; current episode is moderate to severe as demonstrated by documentation of individual's symptoms and their severity or by one or more standardized depression rating scales; is 6 months or less postpartum; Zulresso (brexanolone) is administered as a one-time 60-hour infusion per pregnancy; treatment follows FDA dosing and administration information.age >= 15; postpartum <= 6 months; infusion 60 hours

Zulresso is managed under the medical benefit.

Zurzuvae (zuranolone) initial therapy: Individual is aged 18 years or older; medical record documents DSM-5 diagnostic criteria for Major Depressive Disorder with peripartum onset; current episode is moderate to severe as demonstrated by documentation of individual's symptoms and their severity or by one or more standardized depression rating scales; is 12 months or less postpartum; treatment course is limited to 14 days; treatment follows FDA dosing and administration information.age >= 18; postpartum <= 12 months; course length = 14 days

Zurzuvae is managed under the pharmacy benefit.

Approval Duration and Re-authorization

Length of approval and re-authorization: Initial authorization: Non-formulary exception reviews for all drugs listed in this policy may be approved up to 12 months. Zulresso: one-time infusion per pregnancy only. Zurzuvae: single 14-day treatment course per pregnancy only. Re-authorization beyond these limits is considered not medically necessary.Zulresso: 1 infusion/pregnancy; Zurzuvae: 14 days/course; no repeat beyond limit

Future re-authorization beyond specified limits is considered not medically necessary.

Administration and eligibility criteria (extracted dosing and age guidance)

Usage and dosing requirements described in document sections

Zulresso administration: Zulresso must be administered as a continuous intravenous infusion over 60 hours with stepwise dosing: 0–4 hours: 30 mcg/kg/hour; 4–24 hours: 60 mcg/kg/hour; 24–52 hours: 90 mcg/kg/hour (or 60 mcg/kg/hour if 90 mcg/kg/hour not tolerated); 52–56 hours: 60 mcg/kg/hour; 56–60 hours: 30 mcg/kg/hour.60 hours

Requires continuous monitoring for sedation per boxed warning.

Zurzuvae administration: Zurzuvae (zuranolone) oral dosing: 50 mg once daily in the evening for 14 days; reduce to 40 mg once daily in the evening within the 14-day period if CNS depressant effects occur; for individuals on a strong CYP3A4 inhibitor or with severe hepatic impairment (Child-Pugh C) or severe renal impairment (eGFR < 60 mL/min/1.73 m2) use 30 mg once daily in the evening for 14 days.14 days

Patients may experience CNS depressant effects; follow FDA guidance regarding activity restrictions.

All uses of Zulresso (brexanolone) and Zurzuvae (zuranolone) that are not explicitly described as medically necessary in this policy are considered not medically necessary. The policy defines medical necessity for each product by specific criteria (age, DSM‑5 documentation, severity, postpartum timeframe, and approved administration/course length); uses that fall outside those defined criteria may be denied.

This medical policy does not apply to members covered under a Medicare Advantage plan. Always consult the member benefit booklet or contact a member service representative to confirm coverage and benefit applicability for Medicare Advantage enrollees.

Initial approvals follow the product-specific limits: Zulresso is approved as a one-time 60‑hour infusion per pregnancy and Zurzuvae is approved as a single 14‑day treatment course per pregnancy. Future re‑authorization beyond these limits is considered not medically necessary.

When the policy criteria are not met, treatment with Zulresso or Zurzuvae is considered not medically necessary. Examples include, but are not limited to, exceeding the allowed number or duration of treatment courses per pregnancy (more than one Zulresso infusion per pregnancy or repeat Zurzuvae courses beyond 14 days) or lacking the required documentation (age eligibility, DSM‑5 diagnosis of Major Depressive Disorder with peripartum onset, evidence of moderate to severe depression, or exceeding postpartum time windows).

Coding and Severity Measures

HCPCSHCPCS

J1632

Injection; brexanolone (Zulresso), mg

Included HCPCS (historical mention)HCPCS

J1632

HCPCS code added previously for Zulresso (as noted in history)

Depression rating scale severity thresholds

HAM-D (Hamilton Depression Rating Scale)Score interpretation per policy: ≤10 = Remission; 10–13 = Mild; 14–17 = Mild to moderate; 18–? = Moderate to severe; ≥? = Severe (policy lists ranges with upper bands as shown).

MADRS (Montgomery-Åsberg Depression Rating Scale)0–6 = None; 7–19 = Mild; 20–34 = Moderate; 35+ = Severe.

QIDS‑SR (Quick Inventory of Depressive Symptomatology, Self‑Report)0–5 = None; 6–10 = Mild; 11–15 = Moderate; 16–20 = Severe.

PHQ‑9 (Patient Health Questionnaire‑9)0–4 = None; 5–9 = Mild; 10–14 = Moderate; 15–19 = Moderately severe; 20+ = Severe.

eGFR threshold

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for the drugs covered by this policy. Zulresso (brexanolone) is billed and managed under the medical benefit; Zurzuvae (zuranolone) is billed and managed under the pharmacy benefit. Non-formulary exception review authorizations for all drugs listed in this policy may be approved for up to 12 months. Zulresso is authorized as a one-time 60-hour infusion per pregnancy; re-authorization beyond a one-time infusion per pregnancy is considered not medically necessary. Zurzuvae is authorized as a single 14-day treatment course per pregnancy; re-authorization beyond a single 14-day course per pregnancy is considered not medically necessary. The medications listed in this policy are subject to the product's FDA-approved dosing and administration; dosing must conform to the FDA label.

Prior authorization required
Benefit assignment: Zulresso — medical benefit; Zurzuvae — pharmacy benefit
Initial approvals: Zulresso — one-time 60-hour infusion per pregnancy; Zurzuvae — single 14-day course per pregnancy
Re-authorization: Zulresso — not medically necessary beyond one infusion per pregnancy; Zurzuvae — not medically necessary beyond 14 days per pregnancy
Non-formulary exception authorizations may be approved up to 12 months
Medications must follow FDA dosing and administration

Background on Postpartum Depression and Therapies

Postpartum depression (PPD) is a common complication of childbirth, affecting up to 20% of women, with an overall mean estimated prevalence in the U.S. of approximately 11.5%. A substantial proportion of PPD cases are moderate to severe (reported range 40–80%), and may warrant targeted pharmacologic therapy. Zulresso (brexanolone) and Zurzuvae (zuranolone) are neuroactive steroid GABA‑A receptor positive modulators approved for PPD: Zulresso is administered as a monitored continuous intravenous infusion over 60 hours, and Zurzuvae is given orally as a 14‑day course per FDA labeling.

Definitions and Drug Descriptions

DSM‑5 major depressive episode — diagnostic threshold

Symptom-count thresholdFive (or more) symptoms present during the same 2‑week period representing a change from prior functioning (with at least depressed mood or loss of interest/pleasure).

Required impairment/exclusionSymptoms must cause clinically significant distress or impairment and not be attributable to substances or another medical condition; exclude psychotic and bipolar explanations as specified.

DurationSymptom cluster must be present for the same two‑week period (DSM‑5 major depressive episode criteria).

Standardized depression rating scales — examples and score ranges

HAM‑D example rangesRemission ≤10; 10–13 Mild; 14–17 Mild to moderate; 18–? Moderate to severe; higher scores indicate greater severity (policy lists HAM‑D bands).

Policy Summary

PayerPremera Bluecross

PolicyPharmacologic Treatment of Postpartum Depression

Policy CodePolicy N/A

Change TypeAge eligibility expandedZurzuvae addedAuthorization clarification

Effective DateMar: 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization and document DSM-5 criteria plus severity (narrative or standardized scale) when requesting Zulresso or Zurzuvae.

SourceLink

On This Page

Age eligibility update:

Policy updated to allow use of Zulresso in individuals aged 15 to 17 years supported by adult efficacy, pharmacokinetic, and safety data in 15–17 year olds.

Change recorded in 2022 policy update.

eGFR < 60 mL/min/1.73 m2 qualifies as severe renal impairment for dose adjustment (Zurzuvae dose reduction to 30 mg daily).

ContextThreshold used to trigger Zurzuvae dose reduction to 30 mg once daily for 14 days in individuals with severe renal impairment.

Policy noteDose recommendation applies to Zurzuvae (zuranolone) per administration guidance.

Child‑Pugh — Class C (severe hepatic impairment)

Child‑Pugh class triggering dose changeChild‑Pugh Class C (severe hepatic impairment) — Zurzuvae dose should be reduced to 30 mg once daily for 14 days.

Definition useSevere hepatic impairment (Child‑Pugh C) is specifically cited as a condition requiring Zurzuvae dose reduction.

Applies toDose-modification recommendation applies to Zurzuvae (zuranolone) administration guidance.

Denial Risk

Off‑Label or Other Uses

All uses of Zulresso (brexanolone) and Zurzuvae (zuranolone) that are not outlined in this policy are considered not medically necessary (off-label or other uses). The drugs listed in this policy are subject to the product's FDA dosing and administration; uses outside of those indications or dosing not supported by the FDA label are considered investigational or not medically necessary as specified in the policy.

All other uses not outlined in this policy are not medically necessary
Uses not supported by FDA dosing/administration may be considered investigational

Note

Benefit Limitations and Plan Exclusion

Coverage is subject to the member's benefit plan limits. Providers should verify coverage by consulting the member benefit booklet or contacting member services prior to treatment. Limitations such as benefit exclusions, prior authorization requirements, and quantity/episode limits apply per the member's contract.

Consult member benefit booklet or contact member services for specific coverage
Coverage subject to plan limits, exclusions, and prior authorization

Documentation Required

Required Clinical Documentation and Age/Severity Support

Clinical documentation must include DSM-5 diagnostic criteria for Major Depressive Disorder with peripartum onset and evidence the current episode is moderate to severe. Documentation may be demonstrated by narrative description of symptoms and severity or by one or more standardized depression rating scales. For Zulresso, the individual must be aged 15 years or older and be 6 months or less postpartum. For Zurzuvae, the individual must be aged 18 years or older and be 12 months or less postpartum.

DSM-5 diagnostic criteria for Major Depressive Disorder with peripartum onset documented in medical record
Evidence current episode is moderate to severe (symptom documentation and/or standardized depression rating scale)
Age and postpartum timing: Zulresso — ≥15 years and ≤6 months postpartum; Zurzuvae — ≥18 years and ≤12 months postpartum

Step Therapy

There is no step therapy sequence specified in this policy; no prior trial of other antidepressants is required as a stated policy condition. However, all treatments must adhere to FDA-approved indications and dosing.

No explicit step therapy requirements specified in this policy
Treatments must conform to FDA-approved indications and dosing

0–6 None; 7–19 Mild; 20–34 Moderate; ≥35 Severe.

QIDS‑SR ranges0–5 None; 6–10 Mild; 11–15 Moderate; 16–20 Severe.

PHQ‑9 ranges0–4 None; 5–9 Mild; 10–14 Moderate; 15–19 Moderately severe; ≥20 Severe.

Zulresso (brexanolone) — IV formulation and infusion dosing

FormulationBrexanolone (Zulresso) — intravenous formulation administered as a continuous infusion over 60 hours.

Infusion dosing schedule0–4 hr: 30 mcg/kg/hr; 4–24 hr: 60 mcg/kg/hr; 24–52 hr: 90 mcg/kg/hr (or 60 mcg/kg/hr if 90 not tolerated); 52–56 hr: 60 mcg/kg/hr; 56–60 hr: 30 mcg/kg/hr.

Monitoring noteRequires continuous monitoring for sedation throughout the 60‑hour infusion (boxed warning for excessive sedation).

Zurzuvae (zuranolone) — oral dosing, duration, and dose‑reduction triggers

Formulation and routine doseZuranolone (Zurzuvae) — oral; recommended dose 50 mg once daily in the evening for 14 days.

Dose reduction for CNS effectsIf CNS depressant effects occur during the 14‑day period, reduce dose to 40 mg once daily in the evening.

Dose for drug interactions or organ impairmentFor individuals on strong CYP3A4 inhibitors, or with severe hepatic impairment (Child‑Pugh C) or severe renal impairment (eGFR <60), reduce dose to 30 mg once daily for 14 days.

Safety/driving guidanceZuranolone has a boxed warning for driving impairment; advise patients not to drive or engage in hazardous activities until at least 12 hours after administration.